Legalization Of Marijuana Worldwide

Weed around the world: what legal marijuana looks like in other countries

Canada is on track to become the second country in the world to legalize the consumption and sale of recreational marijuana, after Uruguay made the big leap in 2014.

On Thursday, the Liberal government introduced its Cannabis Act, which allows people aged 18 and over to purchase and consume marijuana.

Much like alcohol, many of the nuts and bolts of legislation will be left to the provinces, who will be able to raise the minimum age if they so wish, and will be required to implement a retail system.

The Trudeau government also plans to punish people for driving under the influence of marijuana, selling it to minors and importing or exporting it without a government permit.

Weed around the world: what legal marijuana looks like in other countries

International Marijuana Laws

Countries all over the world have different perceptions on marijuana. There exists different laws that govern the use, cultivation and distribution of marijuana worldwide. Marijuana use has been continually embraced across many nations, even some engaging in research on marijuana. This article focuses on the different laws in different nations.
South Africa

Marijuana is still an illegal substance in many African states. People still consume weed but without the authorities knowing. However, there have been a new wave that saw a major step taken in South Africa. A couple brought the legalization issue to a high court in Pretoria. Arguments in defence to marijuana stated the economic and medical benefits. In Kenya, there was a motion in the national assembly to fully legalize the use of marijuana. However, there lacked a quorum and the motion could not go through. This shows that soon, African countries will wake up to the reality of the numerous weed benefits.

Several attempts have been done in Canada to legalize weed. There a bill in parliament that dwelt on the legalization of pot. However, the bill did not pass. Recently, the Canadian government has conducted a survey on its citizens to determine its next cause of action. Questionnaires covering several areas such as the type a person likes, the modes of consumption and even the sources. It shows that in the near future, Canada will finally have a legal framework for weed use, a framework that has been denied for the last 90 yea

International Laws

The History and Legality of Cannabis Use Around the World

Why is cannabis labeled as a schedule 1 drug, or in laymen terms, a dangerous, highly addictive substance devoid of any medical benefit? Tobacco has absolutely no medical benefits, is proven to cause cancer, is proven to kill hundreds of thousands of people worldwide, and is one of the most physically and psychologically addictive substances on the planet. However, tobacco, like alcohol, isn’t even scheduled. Additionally, cannabis is scheduled as even more dangerous, more addictive, and less medicinally beneficial then cocaine or methamphetamine, which are labeled as schedule 2 substances. As another example of the illogical scheduling process, psilocybin mushrooms, LSD, and DMT, which have been proven to be highly effective to cure cluster headaches as well as an invaluable tool inpsychotherapy, are labeled as schedule 1 drugs despite these psychedelics having little to no addiction potential. Are you starting to see how silly this is? So what gives? Let’s take a walk through history to find the answer.

Stem cell therapy for Stroke patients

Stem cells secrete deposits near areas of the brain damaged by stroke, and these boost reactivation or regeneration of nerve tissue, which improves motor function.
Visit for more information

In Drug-resistant Epilepsy Patients, Stem Cell Therapy Shows Potential

Stem cell therapy may be a safe and promising treatment option for epilepsy patients who are resistant to antiepileptic drugs, according to new research.

The study, “Treatment of refractory epilepsy patients with autologous mesenchymal stem cells reduces seizure frequency: An open label study,” was published  in the journal Advances in Medical Sciences.

Stem cell therapy consists of using stem cells (immature cells that can become any other cell type in the body) to replace faulty cells and treat patients with a given disease. Many approaches include using the patient’s own stem cells (autologous stem cells), collected from specific organs, such as the bone marrow. This method prevents future complications such as rejection by the body or a response from the person’s immune system.

“Autologous patient-derived [stem cells] represent a stem cell population easy to isolate and expand without ethical or technological limitations,” researchers from the Republic of Belarus wrote.

The Phase 1 trial (NCT02497443) investigated the safety of treating treatment-resistant epilepsy patients with stem cell therapy. Patients received either standard treatment with anti-epileptic drugs (control group), or anti-epileptic drugs combined with a single intravenous administration of their own mesenchymal stem cells (MSC), obtained from their bone marrow, followed by a single injection of MSC through the spinal canal.

The study’s primary endpoint was to assess seizure frequency at one year after the treatment.

Results showed that three in 10 patients receiving stem cell therapy achieved disease remission (indicated by the lack of seizures for one year and more) and five other patients started to respond to treatment with anti-epileptic drugs. In the control group, only two out of 12 patients started to respond to drug treatment.

Of note, injections of stem cell therapy were well-tolerated and did not cause any severe adverse effects.

“Some beneficial effects of the combined cellular therapy on the disease status (MMSE score, seizure frequency and severity, anxiety, and seizure-free remission for more than six months) were observed in the patients of cell therapy group but not in the control group,” the researchers wrote. “Number of responders by seizure frequency in cell therapy group was significantly higher versus the control, and this robust responsiveness (80 percent of cell therapy group) is well in line with other recent observations on clinical effects of … MSCs.”

The study has some limitations: The absence of a placebo-controlled group and the reduced number of patients make it harder to “recommend with confidence the broader application of MSC therapy for epilepsy,” researchers wrote.

They called for future studies with larger populations, a longer follow-up time and optimized stem cell administration to accurately test the long-term therapeutic potential of stem cell therapy in epilepsy.